Vyleesi is the first and only as-needed treatment approved by the Food and Drug Administration (FDA) for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD)
Marks remarkable acceleration in innovation using AI technology
The company has received marketing authorisation for docetaxel from Israel and cytarabine from Colombia
NEIAFMR to be developed as the national hub for folk medicine
The product is expected to be launched in December 2023
Furthering cell therapy ambition across oncology and autoimmune diseases
If approved, patritumab deruxtecan would be a first-in-class HER3 directed DXd antibody drug conjugate for these patients
JB Chemicals will pay Rs 125 crore to Novartis to license the same drug portfolio for the Indian market
The commissioning of the facility represents the culmination of a £45m investment to address rapidly growing demand for ADC manufacturing, supported by a £2.4m Scottish Enterprise grant
The launch of R3SET Detox Candies positions the brand at the forefront of the wellness journey
Subscribe To Our Newsletter & Stay Updated
